Craig-Hallum analyst Adam Vogel initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $43 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MPLT:
- Analyst Reiterates Buy on MapLight, Maintains $37 Price Target on Confidence in ML-007 and Pipeline Upside
- Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged
- MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses
- MapLight Therapeutics reports Q1 EPS ($1.34), consensus ($1.12)
- MapLight Therapeutics initiated with an Outperform at LifeSci Capital